There are currently 23 clinical trials in Murfreesboro, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including International Clinical Research - Tennessee LLC, Tennessee Oncology, PLLC and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/22/2025
Locations: Investigative Site US005, Murfreesboro, Tennessee
Conditions: Hidradenitis Suppurativa
Register for Updates
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498
Recruiting
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2025
Locations: Investigative Site US043, Murfreesboro, Tennessee
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198
Recruiting
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/22/2025
Locations: International Clinical Research - Tennessee (IC Research), Murfreesboro, Tennessee
Conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Register for Updates
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2025
Locations: Investigative Site US232, Murfreesboro, Tennessee
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06548360
Recruiting
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
08/21/2025
Locations: International Clinical Research Tennessee Llc, Murfreesboro, Tennessee
Conditions: NonSegmental Vitiligo
Register for Updates
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952
Recruiting
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/21/2025
Locations: International Clinical Research Tennessee Llc, Murfreesboro, Tennessee
Conditions: Prurigo Nodularis
Register for Updates
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596
Recruiting
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Local Institution - 007-928-F, Murfreesboro, Tennessee
Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Register for Updates
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
NCT06993610
Recruiting
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/14/2025
Locations: International Clinical Research - Tennessee LLC, Murfreesboro, Tennessee
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
Patient Retrospective Outcomes (PRO)
NCT01550575
Recruiting
This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Comprehensive Pain & Neurology Center, Murfreesboro, Tennessee
Conditions: Chronic Pain
Register for Updates
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325
Recruiting
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/07/2025
Locations: Sl0044 50693, Murfreesboro, Tennessee
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462
Recruiting
This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Site Number - 1029, Murfreesboro, Tennessee
Conditions: Rheumatoid Arthritis
Register for Updates
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965
Recruiting
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/07/2025
Locations: International Clinical Research Tennessee Llc, Murfreesboro, Tennessee
Conditions: Prurigo Nodularis
Register for Updates